

ACUTE HEPATOTOXICITY OF *Crotalus durissus terrificus* (SOUTH AMERICAN RATTLESNAKE) VENOM IN RATS

França RF (1), Vieira RP (2), Ferrari EF (1), Souza RA (1), Osorio RAL (1), Prianti-Jr. ACG (1), Hyslop S (3), Zamuner SR (1), Cogo JC (1), Ribeiro W (1)

(1) Laboratory of Physiology and Pharmacodynamic, Institute of Research and Development, Vale do Paraíba University, UNIVAP, São José dos Campos, São Paulo State, Brazil; (2) Department of Pathology and Physical Therapy, School of Medicine, University of São Paulo, USP, São Paulo, São Paulo State, Brazil; (3) Department of Pharmacology, School of Medical Sciences, State University of Campinas, UNICAMP, Campinas, São Paulo State, Brazil.

ABSTRACT: Venom of the South American rattlesnake, *Crotalus durissus terrificus* (Cdt), presents myotoxic and neurotoxic outcomes, but reports on its effects on the liver are scarce. This study examined the hepatotoxicity resulting from Cdt venom administration (100, 200 and 300 µg/kg) in male Wistar rats. Animals were studied at 3, 6, 9 and 12 hours after venom injection. The hepatotoxicity was assessed through serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (AP), gamma glutamyl transferase (GGT), bilirubin and also by histopathological evaluation. All the different concentrations of Cdt venom resulted in increased levels of hepatic enzymes, when compared with the control group, except for the 100 µg/kg dose, which presented normal levels at 9 and 12 hours after venom administration. Bilirubin levels remained unchanged by Cdt venom. Histological analysis revealed endothelial damage, inflammatory cell infiltration, as well as sinusoidal and portal congestion. Based on these observations, we may conclude that Cdt venom causes dose- and time-dependent hepatic damage in rats, characterized by elevated hepatic enzyme levels and histological alterations.

KEY WORDS: *Crotalus durissus terrificus*, hepatotoxicity, histology, AST, ALT, rattlesnake, liver enzymes, venom.

CONFLICTS OF INTEREST: There is no conflict.

FINANCIAL SOURCE: FAPESP and FVE/UNIVAP.

CORRESPONDENCE TO:

WELLINGTON RIBEIRO, Laboratório de Fisiologia e Farmacodinâmica, Instituto de Pesquisa e Desenvolvimento, Universidade do Vale do Paraíba, UNIVAP, Av. Shishima Hifumi, 2911, São José dos Campos, SP, 12.244-000, Brazil. Phone: +55 12 3947 1106. Email: gton@univap.br.

INTRODUCTION

The South American rattlesnake, *Crotalus durissus terrificus*, presents a wide distribution throughout southeastern Brazil (1). Envenomations by this species account for 6 to 8% of all registered bites by venomous snakes in the country, with an approximate mortality rate of 1.8%, the highest among venomous species (2). *C. d. terrificus* venom contains a variety of toxins, including convulxin (3), crotamine (4), crotoxin – its main neurotoxin, which accounts for nearly 50% of the venom dry weight (5) – and gyroxin (6-8), as well as several enzymes common to other snake venoms (9, 10).

Experimental and clinical envenomations by *C. d. terrificus* venom result mainly in myotoxicity and neurotoxicity, while the most effective treatment is administration of anticrotalic antivenom (11). Whereas some consequences of *C. d. terrificus* venom have been extensively studied – such as myonecrosis (12-17), coagulation disturbances (7, 8, 18-20), neuromuscular effects (21, 22), renal involvements (14, 23) and homeostatic problems (20) – considerably less attention has been paid to its effects on the liver.

In humans, envenomation by *C. d. terrificus* causes hepatic lesions involving necrosis, effects attributed to release of pro-inflammatory cytokines (24-27). Also, hepatic steatosis and increased serum aspartate aminotransferase (AST) levels were reported by Azevedo Marques *et al.* (14) in patients bitten by *C. d. terrificus* and extensive hepatic necrosis by Barraviera *et al.* (24). In addition, Barraviera *et al.* (25) showed increased serum levels of AST (86%) and ALT (66%), by hepatocyte electron microscopy that showed mitochondrial damage, suggesting that liver injury may occur partly in the cytoplasm and partly in the mitochondria. Bancher, Rosa and Furlanetto (28) proved that, in mice, the venom could be detected in hepatic tissue.

The liver is a multifunctional organ, responsible for vital functions and for maintenance of energy balance in the organism. The release of intracellular enzymes into circulation is frequently used as an indicator of hepatocyte damage (29), although the release of some enzymes like AST and ALT – also present in tissues other than liver – needs to be evaluated by other injury markers to confirm any hepatic damage. Therefore, in the present study, we examined the liver damage induced by *C. d. terrificus* venom in rats through enzymatic markers of liver function and also by histological analysis.

MATERIALS AND METHODS

Venoms and Reagents

The kits for the quantification of serum enzymes and bilirubin were from Labtest Diagnóstico (Brazil). The reagents for histology were purchased from Synth (Brazil). *C. d. terrificus* venom was obtained by manual milking of snakes (both sexes) collected in the region of São José dos Campos and maintained in the snake house of the Nature Study Center, Vale do Paraíba University. The venom was lyophilized and stored at 4°C. Stock solutions of venom were prepared in sterile 0.9% NaCl immediately before use.

Animals

Male Wistar rats (180-220 g) obtained from Bem-te-vi Farm (Indaiatuba, SP, Brazil) were maintained in a 12-hour-light/dark cycle at 23 ±2°C with free access to food and water. Animal procedures described herein were approved by the institutional Animal Research Ethics Committee of UNIVAP (protocol number L035/2004/CEP) and performed in accord with the guidelines of the Brazilian College for Animal Experimentation (COBEA).

Experimental Protocols

To study the hepatotoxicity of *C. d. terrificus* venom, rats (283 per group) received an intramuscular injection of sterile saline solution only or venom (100, 200 or 300 µg/kg) with saline solution in a final volume of 100 µL. The rats were subsequently killed with an overdose of ether at 3, 6, 9 or 12 hours after saline or venom injection (7 rats/time interval in each group) and blood was collected from the inferior vena cava. Samples of hepatic tissue were also obtained for histological analysis.

Serum Enzyme Activities and Bilirubin Levels

Serum alanine aminotransferase (ALT), alkaline phosphatase (AP), aspartate aminotransferase (AST) and γ-glutamyl transferase (GGT) activities were determined spectrophotometrically, as described by Reitman and Frankel (30), Szasz (31) and Roy (32). Bilirubin tests were made by a chosen diazo-coupling reagent and by a spectrophotometric method, according to Winsten and Cehelyk (33).

Histomorphometrical Analysis

Liver fragments from rats killed at different times after venom administration were fixed in 10% formaldehyde overnight and then dehydrated in an increasing alcohol series, clarified with xylol and embedded in paraffin. Sections of 5- μ m-thick were cut by a microtome (American Optical Co., USA) and stained with hematoxylin and eosin, for subsequent examination and documentation by an Olympus CX-41 $\text{\textcircled{R}}$ microscope (Olympus Optical, USA) fitted to an Olympus PM10SP Automatic Photomicrographic $\text{\textcircled{R}}$ system (Olympus America Medical, USA). Twenty fields were analyzed for each slide. Using a 100-point grid with a known area (10,000 μm^2 at 1,000x magnification) attached to the microscope lens the number of points contacting the Kupffer cells and leukocytes were counted within a total area (10,000 μm^2). The density of congested blood vessels, endothelial area and degenerated hepatocytes were counted and the values adjusted to the total tissue area (10,000 μm^2). The density of Kupfer and mononuclear cells, as well as the density of congested blood vessels, endothelial area and degenerated hepatocytes were expressed as number of cells/ mm^2 of tissue. For a qualitative histological evaluation, the following criteria were used to determine the histologic score (scale 0-10): 0 = negative; 0.5 to 2.0 = mild; 2.5 to 5.5 = moderate; 6.0 to 8.0 = severe; 8.5 to 10.0 = very severe (34).

Statistical Analysis

The results were expressed as mean \pm SEM and statistical comparisons were performed by Student's t-test or one-way of variance (Anova) followed by the Tukey-Kramer test. The p value was considered significant ($p < 0.05$); very significant ($p < 0.01$) and extremely significant ($p < 0.001$).

RESULTS

Serum Liver Enzyme Activities and Bilirubin Levels

Figure 1A shows the changes in AST levels at various time intervals following the injection of different doses of *C. d. terrificus* venom. The administration of 100 $\mu\text{g}/\text{kg}$ of the venom resulted in increased AST activity at 3 hours when compared to the control group ($p < 0.05$), but no differences after 6, 9 and 12 hours ($p > 0.05$). Regarding the 200- and 300- $\mu\text{g}/\text{kg}$ venom doses, we observed an increased AST activity at all times (3, 6, 9 and 12 hours) relative to the control group ($p < 0.05$).

Figure 1B reveals the changes in ALT levels at diverse intervals after administration of different concentrations of *C. d. terrificus* venom. Concerning the 100- $\mu\text{g}/\text{kg}$ dose, no changes in ALT activity was found, when compared with the control group at 3, 6, 9 and 12 hours ($p > 0.05$). The 200- $\mu\text{g}/\text{kg}$ concentration of *C. d. terrificus* venom augmented ALT activity only at 9 and 12 hours relative to the control group ($p < 0.05$). At the dose of 300 $\mu\text{g}/\text{kg}$ of *C. d. terrificus* venom, the ALT activity was greater than in the control group at 3, 6, 9 and 12 hours ($p < 0.05$).

AP activity increased progressively after the administration of all venom doses, although a significant change was seen only with the highest dose (300 $\mu\text{g}/\text{kg}$) at 12 hours post-venom (Figure 1C). GGT levels showed a peak increase 6 hours after administration of the lowest dose, with a return to the pre-venom levels at 12 hours post-venom. A moderate and persistent rise in GGT activity was registered with the intermediate dose (200 $\mu\text{g}/\text{kg}$), while the highest one produced a progressive increase during the 12 hours after venom administration (Figure 1D). Figure 1E shows that total bilirubin levels were not changed by any venom dose or time interval.




Figure 1. Serum enzyme activities and bilirubin levels. Enzymes were collected from rat sera 3, 6, 9 and 12 hours after administration of 100, 200 and 300 µg/kg of Cdt venom. (A) Alanine aminotransferase (ALT); (B) aspartate aminotransferase (AST); (C) alkaline phosphatase (AP); (D) gamma glutamyl transferase (GGT) and (E) total bilirubin concentration. Data expressed as mean values ± S.E.M for 7 rats per group; *p < 0.05 when compared to the control group and analyzed by one-way Anova, followed by Tukey-Kramer multiple comparisons test.

Histological Analysis

Sections of hepatic tissue from saline-treated (control) rats showed normal hepatocytes with strongly stained nuclei and protein-rich cytoplasm. Transversal sections showed intact sinusoids, portal spaces and a lobular central vein (Figure 2A). In contrast, rats injected with 100 µg/kg showed damage caused by an inflammatory infiltrate 3 and 6 hours after venom injection (Figure 2B). At 9 and 12 hours post-venom, the appearance of the tissue had returned to normal (Figure 2C). However, the morphometric analysis did not show statistical differences between the control group and 100 µg/kg group. At the venom dose of 200 µg/kg, copious cellular infiltrate and the extent of damage augmented with time (Figure 2D). The morphometric analysis showed that at 200 µg/kg at 12 hours, the densities of Kupfer cells, endothelium and degenerated hepatocytes were increased when compared with the control group. The density of congested blood vessels at 9 hours was higher than in the control group. At the highest venom dose (300 µg/kg), the hepatocytes showed marked disorganization, with swelling, necrosis and a progressive increase in damage up to 12 hours after venom administration (Figure 2E). Moreover, the histomorphometric findings demonstrate in Table 1 that at 9 hours, the density of Kupfer cells, congested blood vessels, endothelium densities and degenerated hepatocyte were greater than in those of control group. At 12 hours, all parameters were elevated when compared with the control group.




Figure 2. Histological analysis. **(A)** Photomicrograph of hepatic tissue from the control group (HE, 400x). See hepatic artery (\rightarrow), biliary duct ($\bullet \rightarrow$), portal vein (\leftrightarrow). **(B)** Photomicrograph of hepatic tissue 6 hours after venom injection (100 $\mu\text{g}/\text{kg}$) (HE, 400x). Observe vascular congestion (\star), inflammatory infiltrate ($\bullet \rightarrow$) and increased density of Kupffer cells (\rightarrow). **(C)** Photomicrograph of hepatic tissue 12 hours after venom injection (100 $\mu\text{g}/\text{kg}$) (HE, 400x). A few inflammatory cells and plate hepatocytes. **(D)** Photomicrograph of hepatic tissue 6 hours after venom injection (200 $\mu\text{g}/\text{kg}$) (HE, 400x). Dense inflammatory infiltrate and portal vein congestion. **(E)** Photomicrograph of hepatic tissue 12 hours after venom injection (300 $\mu\text{g}/\text{kg}$) (HE, 400x). Damaged hepatic vascular system showing high inflammatory infiltrate; hepatocyte degeneration.

Table 1. Morphometric analysis of liver histological aspects

		Kupffer cells/mm²	Inflammatory infiltrate/mm²	Blood vessel congestion/mm²	Endothelial density/mm²	Hepatocyte degeneration/mm²
Control		1.00±0.78	1.68±1.23	0.63±0.47	0.16±0.14	0.26±0.32
	3h	2.47±0.92	6.00±1.22***	2.95±1.16*	0.68±0.34	1.42±0.37
Venom 100	6h	2.74±0.76	7.37±1.36***	3.16±0.81*	1.63±1.02	1.84±0.92
	9h	1.53±0.71	2.37±0.69	1.26±0.54	0.68±0.78	1.010±0.43
µg/kg	12h	2.06±1.34	2.05±0.83	0.95±0.39	0.26±0.20	0.79±0.84
	3h	2.47±0.71	5.58±1.26***	2.21±0.51	1.16±0.47	1.84±0.81
Venom 200	6h	4.53±0.82***	4.90±1.54***	4.95±1.05***	1.63±0.69	3.90±0.66***
	9h	4.10±0.99***	4.74±1.43**	5.16±1.92***	1.95±1.05*	4.00±1.44***
µg/kg	12h	6.47±1.60***	4.95±0.94***	3.58±2.26**	3.68±1.12***	4.05±1.05***
	3h	3.21±0.62*	4.79±1.06**	5.21±1.06***	3.37±0.91***	3.95±1.05***
Venom 300	6h	4.21±1.18***	5.58±1.81***	6.53±1.37***	3.47±1.60***	3.95±1.05***
	9h	6.05±1.61***	5.26±0.98***	8.11±1.88***	5.16±1.14***	5.63±0.91***
µg/kg	12h	6.74±1.76***	6.10±1.66***	9.58±0.37***	7.74±1.54***	6.00±0.78***

Morphometric analysis of liver histological aspects found in the control group and Cdt venom group (100 µg/kg; 200 µg/kg and 300 µg/kg) 3, 6, 9 and 12 hours after administration (7 rats per group). Data expressed as intensity score scale from 0 to 10: 0 = negative; 0.5 to 2.0 = mild; 2.5 to 5.5 = moderate; 6.0 to 8.0 = severe; 8.5 to 10.0 = very severe. *p < 0.05; **p < 0.01 and ***p < 0.001 vs. shocked rats treated with saline (Kruskal-Wallis test).

DISCUSSION

The present study showed that the *Crotalus durissus terrificus* venom augments activity of hepatic enzymes and also produces histological alterations, suggesting hepatotoxicity.

The liver maintains the organism's energy supply for many functions, such as producing substances that break down fats, converting glucose to glycogen, producing urea, synthesizing certain amino acids, filtering harmful substances and maintaining a proper blood glucose level. There are some intracellular enzymes that are released into the circulation and are frequently used as an indicator of damage to hepatocytes. The principal marker enzymes include alanine (ALT) and aspartic (AST) aminotransferases, which catalyze the transfer of α -amino groups from alanine and aspartate to the α -keto group of ketoglutaric acid to produce pyruvic acid and oxaloacetic acid, respectively (29). ALT is a more specific marker of hepatocellular injury, and occurs in the liver, kidneys, heart, skeletal muscle and pancreas, whereas AST has a wider distribution, occurring in organs such as heart, liver, skeletal muscles, kidneys and pancreas. In the liver, AST occurs predominantly (80%) in mitochondria and 20% in the cytoplasm, whereas ALT is confined to the cytoplasm (29, 35). Other enzymes such as alkaline phosphatase (AP) and γ -glutamyl transferase (GGT) may also be used as markers of hepatic dysfunction, although they are found in the liver, bone, the kidneys and its enhancement is related to production elevation or excretion deficit, such as obstructive jaundice and cholestasis. GGT is present in the liver, kidney and pancreas. Bilirubin is a pigment derived from the catabolism of the heme radical in hemoproteins such as hemoglobin, while increased serum levels of this pigment can indicate cholestatic processes and hepatocellular damage.

The measurement of serum enzyme activities in clinical studies, after *C. d. terrificus* venom administration, showed increased levels of creatine kinase (14, 16, 18, 36), creatine phosphokinase (14), lactate dehydrogenase (14, 16, 36), aspartate aminotransferase (36) and glutamic-oxaloacetic transaminase (14), primarily as consequences of venom myotoxic action (11), as well as injury markers of cardiac muscle disturbance similar to those of skeletal muscles (7, 36). Serum levels of alkaline phosphatase and alanine aminotransferase were also elevated in dogs treated with *C. d. terrificus* venom (1 mg/kg, IM) (20). Approximately half of the

patients bitten by *C. d. terrificus* show coagulation disorders primarily mediated by thrombin-like enzymes present in this venom (8, 18).

A study in dogs revealed that *C. d. terrificus* venom causes marked alterations in hematological, hemostatic and biochemical parameters that may also be seen, through histological examination, as intravascular coagulation in cardiac and hepatic tissues (20). These authors also showed a progressive increase of serum levels of myoglobin, creatine kinase and aspartate aminotransferase demonstrated that animals developed rhabdomyolysis. On the other hand, AP did not increase expressly. Probably, this is related to cholestatic diseases, which is plausible because, like AP, bilirubin concentration did not increase over time and, as outlined in the preceding sections, is also related to cholestatic process (35-37).

As proven by the current study, the administration of *C. d. terrificus* venom to rats resulted in increased circulating levels of enzymes (ALT, AST and GGT) that are frequently employed as indicators of hepatic damage and cholestasis. The increased AST levels observed in the present work are similar to elevated serum activity of the same enzyme after human envenomations (24, 11). Changes in serum levels of other enzymes, including creatine kinase (CK) and lactate dehydrogenase (LDH), have also been observed in human envenomations (11). However, there are differences in kinetic profiles of these alterations. For example, CK and LDH levels present their peaks respectively before and after other enzymes. The hepatic damage caused by the smallest venom dose (100 µg/kg), assessed by enzyme release and histological analysis (Table 1), appeared to be minimal and reversible. Higher venom doses (200 and 300 µg/kg) resulted in greater damage that was not reversible within the time scale of the present experiments. In part, this hepatotoxicity is probably mediated by PLA₂ component of crotoxin, which presents the ability to interfere in hepatic mitochondrial respiration (38). The presence of inflammatory infiltrates associated with severe damage indicates that *C. d. terrificus* venom and its components are capable of affecting macrophage function and stimulating cytokine production (39, 40). These findings agree with the demonstrations of acute phase inflammatory reactions in humans bitten by *C. d. terrificus* (26).

The venom components responsible for the hepatotoxicity are still undetermined, but they probably involve PLA₂ action on cell membrane lipids and mitochondrial respiration (38), as well as various cell types such as lymphocytes (41, 42), macrophages (39, 40, 43, 44), mast cells (45), and platelets (3, 46-49). In support of

this conclusion, crotoxin – which presents all PLA₂ activity of *C. d. terrificus* venom – has been implicated in numerous effects, including neurotoxicity (22), myotoxicity (12, 50, 51), renal toxicity (52), edema (45, 51), inhibition of macrophage activity (40, 44), immunosuppression (42), stimulation of the hypothalamo-pituitary-adrenal axis (including increased plasma glucose, ACTH, corticosterone and TNF- α levels) and of corticotropin-releasing hormone (CRH) and of arginine vasopressin pathways (53), and cytostatic (54) and cytotoxic (55) effects in cancer cell lines.

Coagulation disturbances (19, 20) leading to fibrin deposition and ischemia, mainly through the action of the thrombin-like enzyme (gyroxin) of this venom (8, 9, 19) could also contribute to the hepatic damage registered in the present study. In addition, considering the inter- and intrasubspecific variation in the composition and biological activities of this venom (51, 56-61), there may be differences in hepatic effects produced by venoms obtained from *C. d. terrificus* specimens from other regions, and among other subspecies like *C. d. cascavella*, *C. d. collilineatus*, *C. d. durissus* and *C. d. ruruima*. Finally, diverse susceptibilities of animal strains and species (18) may also contribute to variations in hepatic effects of this venom.

The present study provides evidence that *Crotalus durissus terrificus* venom induces hepatotoxicity in rats, by increasing blood liver enzymes, probably derived from liver, since histological analysis revealed augmented endothelium density and hepatic damage.

ACKNOWLEDGEMENTS

This work was supported by the State of São Paulo Research Foundation (FAPESP, grant n. 2001/12486-8) and Valeparaibana Teaching Foundation (FVE/UNIVAP). R. F. França was supported by a FAPESP studentship (grant n. 02/11642-9). R. P. Vieira was supported by a FAPESP post-doc studentship (grant n. 2007/01026-2). S. Hyslop is supported by a research fellowship from the National Council for Scientific and Technological Development (CNPq).

REFERENCES

1. Campbell JA, Lamar WW. The venomous reptiles of Latin America. Ithaca: Cornell University Press; 1989. 425 p.
2. Araújo FAA, Santalúcia M, Cabral RF. Epidemiologia dos acidentes por animais peçonhentos. In: Cardoso JLC, França FOS, Wen FH, Málaque CMS, Haddad Junior V, editors. Animais Peçonhentos no Brasil: biologia, clínica e terapêutica dos acidentes. São Paulo: Sarvier; 2003. p. 6-12.
3. Prado-Franceschi J, Brazil OV. Convulxin, a new toxin from the venom of the South American rattlesnake *Crotalus durissus terrificus*. Toxicon. 1981;19(6):875-87.
4. Goncalves JM. Purification and properties of crotamine. In: Buckley EE, Porgee N, editors. Venoms. Washington: American Association for the Advancement of Science; 1956. p. 261-274.
5. Slotta KH, Fraenkel-Conrat HL. Schlangengifte, III. Mitteil.: Reinigung und krystallisation des klapperschlangen-giftes. Ber Dtsch Chem Ges. 1938;71(5):1076-81.
6. Seki C, Vidal JC, Barrio A. Purification of gyroxin from a South American rattlesnake (*Crotalus durissus terrificus*) venom. Toxicon. 1980;18(3):235-47.
7. Siqueira JE, Higuchi ML, Nabut N, Lose A, Souza JK, Nakashima M. Lesão miocárdica em acidente ofídico pela espécie *Crotalus durissus terrificus* (cascavel), relato de caso. Arq Bras Cardiol. 1990;54(5):323-5.
8. Alexander G, Grothusen J, Zepeda H, Schwartzman RJ. Gyroxin, a toxin from the venom of *Crotalus durissus terrificus*, is a thrombin-like enzyme. Toxicon. 1988;26(10):953-60.
9. Raw I, Rocha MC, Esteves MI, Kamiguti AS. Isolation and characterization of a thrombin-like enzyme from the venom of *Crotalus durissus terrificus*. Braz J Med Biol Res. 1986;19(3):333-8.
10. Bercovici D, Chudziniski AM, Dias VO, Esteves MI, Hiraichi E, Oishi NY, Picarelli ZP, Rocha MC, Ueda CMPM, Yamanouye N, Raw I. A systemic fractionation of *Crotalus durissus terrificus* venom. Mem Inst Butantan. 1987;49(3):69-78.
11. Azevedo-Marques MM, Hering SE, Cupo P. Acidente crotálico. In: Cardoso JLC, França FOS, Wen FH, Málaque CMS, Haddad Jr V, editors. Animais Peçonhentos no Brasil, biologia, clínica e terapêutica dos acidentes. São Paulo: Sarvier; 2003.

12. Gopalakrishnakone P, Dempster DW, Hawgood BJ, Elder HY. Cellular and mitochondrial changes induced in the structure of murine skeletal muscle by crotoxin, a neurotoxic phospholipase A2 complex. *Toxicon*. 1984;22(1):85-98.
13. Lima MR, dos Santos MC, Tambourgi DV, Marques T, da Silva WD, Kipnis T. Susceptibility of different strains of mice to South American rattlesnake (*Crotalus durissus terrificus*) venom: correlation between lethal effect and creatine kinase release. *Toxicon*. 1991;29(6):783-6.
14. Azevedo-Marques MM, Cupo P, Coimbra TM, Hering SE, Rossi MA, Laure CJ. Myonecrosis, myoglobinuria and acute renal failure induced by South American rattlesnake (*Crotalus durissus terrificus*) envenomation in Brazil. *Toxicon*. 1985;23(4):631-6.
15. Azevedo-Marques MM, Hering SE, Cupo P. Evidence that *Crotalus durissus terrificus* (South American rattlesnake) envenomation in humans causes myolysis rather than hemolysis. *Toxicon*. 1987;25(11):1163-8.
16. Cupo P, Azevedo-Marques MM, Hering SE. Clinical and laboratory features of South American rattlesnake (*Crotalus durissus terrificus*) envenomation in children. *Trans R Soc Trop Med Hyg*. 1988;82(6):924-9.
17. Rossi MA, Peres LC, de Paola F, Cupo P, Hering SE, Azevedo-Marques MM. Electron-microscopic study of systemic myonecrosis due to poisoning by tropical rattlesnake (*Crotalus durissus terrificus*) in humans. *Arch Pathol Lab Med*. 1989; 113(2):169-73.
18. Jorge MT, Ribeiro LA. Epidemiologia e quadro clínico do acidente por cascavel sul-americana (*Crotalus durissus*). *Rev Inst Med Trop São Paulo*. 1992;34:347-54.
19. Marunak SL, Acosta OC, Leiva LC, Ruiz RM, Aguirre MV, Teibler P. Mice plasma fibrinogen consumption by thrombin-like enzyme present in rattlesnake venom from the North-east region of Argentina. *Medicina*. 2004;64(6):509-17.
20. Sousa e Silva MC, Tomy SC, Tavares FL, Navajas L, Larsson MH, Lucas SR, Kogika MM, Sano-Martins IS. Hematological, hemostatic and clinical chemistry disturbances induced by *Crotalus durissus terrificus* snake venom in dogs. *Hum Exp Toxicol*. 2003;22(9):491-500.
21. Barrio A, Brazil OV. Neuromuscular action of the *Crotalus terrificus terrificus* (Laur.) poisons. *Acta Physiol Lat Am*. 1951;1(4):291-308.
22. Gopalakrishnakone P, Hawgood BJ. Morphological changes induced by crotoxin in murine nerve and neuromuscular junction. *Toxicon*. 1984;22(5):791-804.

23. Monteiro HS, da Silva IM, Martins AM, Fonteles MC. Actions of *Crotalus durissus terrificus* venom and crotoxin on the isolated rat kidney. Braz J Med Biol Res. 2001;34(10):1347-52.
24. Barraviera B, Bonjorno-Júnior JC, Arakaki D, Domingues MA, Pereira PC, Mendes RP, Machado JM, Meira DA. A retrospective study of 40 victims of *Crotalus* snake bites. Analysis of the hepatic necrosis observed in one patient. Rev Soc Bras Med Trop. 1989;22(1):5-12.
25. Barraviera B, Coelho KY, Curi PR, Meira DA. Liver dysfunction in patients bitten by *Crotalus durissus terrificus* (Laurenti, 1768) snakes in Botucatu (state of São Paulo, Brazil). Rev Inst Med Trop São Paulo. 1995;37(1):63-9.
26. Barraviera B, Lomonte B, Tarkowski A, Hanson LA, Meira DA. Acute-phase reactions, including cytokines, in patients bitten by *Bothrops* and *Crotalus* snakes in Brazil. J Venom Anim Toxins. 1995;1(1):11-22.
27. Wajchenberg BL, Sesso J, Inague T. Feições clínico-laboratoriais do envenenamento crotálico humano. Rev Ass Med Bras. 1954;1:179-93.
28. Bancher W, Rosa RR, Furlanetto RS. Estudos sobre a fixação eletiva e quantitativa do veneno de *Crotalus durissus terrificus* nos tecidos nervoso, renal, hepático e muscular de *Mus musculus* Linneus, 1758. Mem Inst Butantan. 1973;37:139-48.
29. Rodrigues LEA. Enzimologia Clínica. Rio de Janeiro: Revinter; 2001. 157 p.
30. Reitman S, Franke L S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol. 1957;28(1):56-63.
31. Szasz G. A kinetic photometric method for serum gamma-glutamyl transpeptidase. Clin Chem. 1969;15(2):124-36.
32. Roy AV. Rapid method for determining alkaline phosphatase activity in serum with thymolphthalein monophosphate. Clin Chem. 1970;16:431-6.
33. Winsten S, Cehelyk B. A rapid micro diazo technique for measuring total bilirubin. Clin Chim Acta. 1969;25(3):441-6.
34. Heijne WH, Lamers RJ, van Bladeren PJ, Groten JP, van Nesselrooij JH, van Ommen B. Profiles of metabolites and gene expression in rats with chemically induced hepatic necrosis. Toxicol Pathol. 2005;33(4):425-33.
35. Gayotto LCC, Alves VAF. Doenças do fígado e vias biliares. São Paulo: Atheneu; 2001. 664 p.

36. Cupo P, Azevedo-Marques MM, Hering SE. Acute myocardial infarction-like enzyme profile in human victims of *Crotalus durissus terrificus* envenoming. Trans R Soc Trop Med Hyg. 1990;84(3):447-51.
37. Mattos AA, Dantas W. Compêndio de hepatologia. 2nd ed. São Paulo: Fundo Editorial Byk; 2001. 919 p.
38. Valente RH, Novello JC, Marangoni S, Oliveira B, Pereira-da-Silva L, Macedo DV. Mitochondrial swelling and oxygen consumption during respiratory state 4 induced by phospholipase A2 isoforms isolated from the South American rattlesnake (*Crotalus durissus terrificus*) venom. Toxicon. 1998;36(6):901-13.
39. Sampaio SC, Sousa e Silva MCC, Borelli P, Curi R, Cury Y. *Crotalus durissus terrificus* snake venom regulates macrophage metabolism and function. J Leukoc Biol. 2001;70(4):551-8.
40. Sampaio SC, Brigatte P, Sousa e Silva MC, dos Santos EC, Rangel-Santos AC, Curi R, Cury R. Contribution of crotoxin for the inhibitory effect of *Crotalus durissus terrificus* snake venom on macrophage function. Toxicon. 2003;41(7):899-907.
41. Garcia F, Toyama MH, Castro FR, Proença PL, Marangoni S, Santos LMB. Crotopotin induced modification of T lymphocyte proliferative response through interference with PGE2 synthesis. Toxicon. 2003;42(4):433-7.
42. Rangel-Santos A, Lima C, Lopes-Ferreira M, Cardoso DF. Immunosuppressive role of principal toxin (crotoxin) of *Crotalus durissus terrificus* venom. Toxicon. 2004;44(6):609-16.
43. Martins AMC, Lima AAM, Toyama MH, Marangoni S, Fonteles MC, Monteiro HSA. Renal effects of supernatant from macrophages activated by *Crotalus durissus cascavella* venom: the role of phospholipase A2 and cyclooxygenase. Pharmacol Toxicol. 2003;92(1):14-20.
44. Sampaio SC, Rangel-Santos AC, Peres CM, Curi R, Cury Y. Inhibitory effect of phospholipase A2 isolated from *Crotalus durissus terrificus* venom on macrophage function. Toxicon. 2005;45(5):671-6.
45. Camara PRS, Esquisatto LCM, Camargo E, Ribela M, Toyama MH, Marangoni S, Nucci G, Antunes E. Inflammatory edema induced by phospholipases A2 isolated from *Crotalus durissus* sp. in the rat dorsal skin: a role for mast cells and sensory C-fibers. Toxicon. 2003;41(7):823-9.

46. Francischetti IM, Saliou B, Leduc M, Carlini CR, Hatmi M, Randon J, Faili A, Bon C. Convulxin, a potent platelet-aggregating protein from *Crotalus durissus terrificus* venom, specifically binds to platelets. *Toxicon*. 1997;35(8):1217-28.
47. Francischetti IM, Ghazaleh FA, Reis RAM, Carlini CR, Guimarães JA. Convulxin induces platelet activation by a tyrosine kinase-dependent pathway and stimulates tyrosine phosphorylation of PLC-Gamma2, independently of integrin $\alpha\text{IIb}\beta\text{3}$. *Arch Biochem Biophys*. 1998;353:239-50.
48. Jandrot-Perrus M, Lagrue AH, Okuma M, Bon C. Adhesion and activation of human platelets induced by convulxin involve glycoprotein VI and integrin $\alpha\text{2}\beta\text{1}$. *J Biol Chem*. 1997;272(43):27035-41.
49. Polgár J, Clemetson JM, Kehrel BE, Wiedemann M, Magnenat EM, Wells TN, Clemetson KJ. Platelet activation and signal transduction by convulxin, a C-type lectin from *Crotalus durissus terrificus* (tropical rattlesnake) venom via the p62/GPVI collagen receptor. *J Biol Chem*. 1997;272(21):13576-83.
50. Miyabara EH, Tostes RC, Selistre-de-Araújo HS, Aoki MS, Moriscot AS. Role of nitric oxide in myotoxic activity induced by crotoxin *in vivo*. *Toxicon*, 2004;43(4):425-32.
51. Rangel-Santos A, dos Santos EC, Lopes-Ferreira M, Lima C, Cardoso DF, Mota I. A comparative study of biological activities of crotoxin and CB fraction of venoms from *Crotalus durissus terrificus*, *Crotalus durissus cascavella* and *Crotalus durissus collilineatus*. *Toxicon*. 2004;43(7):801-10.
52. Martins AM, Toyama MH, Havt A, Novello JC, Marangoni S, Fonteles MC, Monteiro HS. Determination of *Crotalus durissus cascavella* venom components that induce renal toxicity in isolated rat kidneys. *Toxicon*. 2002;40(8):1165-71.
53. Chisari A, Spinedi E, Voirol MJ, Giovambattista A, Gaillard RC. A phospholipase A2-related snake venom (from *Crotalus durissus terrificus*) stimulates neuroendocrine and immune functions: determination of different sites of action. *Endocrinology*. 1998;139(2):617-25.
54. Donato NJ, Martin CA, Perez M, Newman RA, Vidal JC, Etcheverry M. Regulation of epidermal growth factor receptor activity by crotoxin, a snake venom phospholipase A2 toxin. A novel growth inhibitory mechanism. *Biochem. Pharmacol*. 1996;51(11):1535-43.
55. Corin RE, Viskatis LJ, Vidal JC, Etcheverry MA. Cytotoxicity of crotoxin on murine erythroleukemia cells *in vitro*. *Invest. New Drugs*. 1993;11(1):11-5.

56. Faure G, Bon C. Crotoxin, a phospholipase A2 neurotoxin from the South American rattlesnake *Crotalus durissus terrificus*: purification of several isoforms and comparison of their molecular structure and of their biological activities. Biochemistry. 1988;27(2):730-8.
57. Faure G, Bon C. Several isoforms of crotoxin are present in individual venoms from the South American rattlesnake *Crotalus durissus terrificus*. Toxicon. 1987;25(2):229-34.
58. Faure G, Choumet V, Bouchier C, Camoin L, Guillaume JL, Monegier B, Vuilhorgne M, Bon C. The origin of the diversity of crotoxin isoforms in the venom of *Crotalus durissus terrificus*. Eur J Biochem. 1994;223(1):161-4.
59. Santoro ML, Sousa e Silva MCC, Gonçalves LRC, Almeida-Santos SM, Cardoso DF, Laporte-Ferreira IL, Saiki M, Peres CA, Sano-Martins IS. Comparison of the biological activities in venoms from three subspecies of the South American rattlesnake (*Crotalus durissus terrificus*, *C. durissus cascavella* and *C. durissus collilineatus*). Compl Biochem Physiol C Pharmacol Toxicol Endocrinol. 1999;122(1):61-73.
60. Francischetti IM, Gombarovits ME, Valenzuela JG, Carlini CR, Guimarães JA. Intraspecific variation in the venoms of the South American rattlesnake (*Crotalus durissus terrificus*). Comp Biochem Physiol C Toxicol Pharmacol. 2000;127(1):23-36.
61. Saravia P, Rojas E, Arce V, Guevara C, Lopez JC, Chaves E, Velasquez R, Rojas G, Gutiérrez JM. Geographic and ontogenic variability in the venom of the neotropical rattlesnake *Crotalus durissus*: pathophysiological and therapeutic implications. Rev Biol Trop. 2002;50(1):337-46.